Visiongain Publishes Plasma Protein Therapeutic Market Report 2020-2030

30 July 2020
Pharma

Visiongain has launched a new report Plasma Protein Therapeutic Market Report 2020-2030: Forecasts by Product (Albumin, Immunoglobulin, Alpha-1 Proteinase Inhibitor, Coagulation Factors), by Application (Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Others), and by Region (North America, Europe, Asia Pacific, Latin America & MEA), Including Forecasts by Major Developed Countries and Developing Countries, Plus Profiles of Leading Companies.

Plasma is a protein-rich fluid and 90% of it is made of water. Some of the functions of plasma proteins are clotting of blood, transport of various biochemical components in the circulatory systems and immunity against diseases. Different types of diseases such as neurological, autoimmune, and autoimmune diseases can be treated by isolating proteins from plasma. In this type of therapeutics, the deficient or missing type of protein is replaced using plasma protein. Infusion and injecting these plasma proteins can also be used to chronic and genetic diseases.

The increase in the use of plasma protein in the pharmaceutical industry for the treatment of various blood disorders and autoimmune diseases is the major factor boosting the demand for plasma protein therapeutics. Plasma proteins can be used as replacement therapies to treat different blood conditions such as dysfibrinogenemia, deficiency of a coagulation factor, and afibrinogenemia. Moreover, the technological advancements, increase in disposable income globally, and availability of favourable reimbursements helps to drive the market growth. Technological advancement to improve the efficacy of plasma proteins and enhancing the technique of sample plasma extraction will further increase the demand for plasma proteins therapy.

The increase in geriatric population, optimization of downstream process, and increasing number of applications further drives the growth of global plasma protein therapeutic market. As per the data by WHO, the geriatric population is expected to increase to 16% of the global population by 2050 as compared to 7% of the global population that were above 65 years in 2000. As the elderly population are more prone to suffer from cardiovascular and neurological diseases, the increase in elderly population will increase the demand for plasma protein therapeutics. Plasma proteins are increasing being used for the treatment of various other disease such as sepsis, myasthenia gravis, malaria, and Alzheimer’s disease. However, the issues related to manufacturing and storage in developing countries and slow approval process are expected to hamper the market growth.

The Visiongain report analyst commented “the increase in use of plasma protein as biotherapeutics, increase in R&D activities to use plasma proteins for number of applications, and high demand for advanced therapeutics are the major driving factors for growth of the plasma protein therapeutic market”.

The report covers a detailed competitive outlook that includes market share and company profiles of key players operating in the global market. Key players profiled in the report include CSL Behring LLC, Baxter International, China Biologics, Octapharma AG, Grifols S.A., Shire Plc, Bayer AG, Biotest AG, and Kedrion S.P.A.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Viral Vectors & Plasmid DNA Manufacturing Market Report 2021-2031

Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.

03 December 2020

Read

Visiongain Publishes Drugs of Abuse Testing Market Report 2021-2031

Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.

03 December 2020

Read

Visiongain Publishes Controlled Substance Market Report 2021-2031

Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.

03 December 2020

Read

Visiongain Publishes Companion Animal Diagnostics Market Report 2021-2031

All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.

03 December 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever